^
Association details:
| Biomarker: | BRCA2 mutation |
|---|---|
| Cancer: | Triple Negative Breast Cancer |
| Drug Class: | PARP inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Chemo- and Targeted Therapy for Patients With HER2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative
Published date:
07/29/2021
Excerpt:
Patients with triple-negative MBC with germline BRCA mutations previously treated with chemotherapy may be offered a poly (ADP-ribose) polymerase inhibitor rather than chemotherapy
DOI:
10.1200/JCO.21.01374
Source:
Title:
Efficacy and Safety of PARP Inhibitors in Advanced or Metastatic Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis
Published date:
10/28/2021
Excerpt:
In subgroup analysis, patients with BRCA mutation had a higher objective response to PARP inhibitor, with an RR of 2.85 (95%CI, 1.34–6.06; p = 0.007)...Compared with patients without germline BRCA mutation, patients with germline BRCA mutation could benefit more from PARP inhibitors.
DOI:
https://doi.org/10.3389/fonc.2021.742139
Source:
Title:
Deep exploration of PARP inhibitors in breast cancer: monotherapy and combination therapy
Published date:
02/04/2021
Excerpt:
PARPi monotherapy can significantly improve clinical outcomes in patients with advanced breast cancer, especially those with TNBC, those who had not previously received platinum therapy, and those with mutant BRCA1/2.
DOI:
10.1177/0300060521991019
